Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueDepreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsReceivables - Net
Ratios

Insight Molecular Diagnostics (IMDX) Leases (2020 - 2025)

Insight Molecular Diagnostics (IMDX) has disclosed Leases for 6 consecutive years, with $1.7 million as the latest value for Q4 2025.

  • Quarterly Leases rose 76.34% to $1.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.7 million through Dec 2025, up 76.34% year-over-year, with the annual reading at $1.7 million for FY2025, 76.34% up from the prior year.
  • Leases hit $1.7 million in Q4 2025 for Insight Molecular Diagnostics, down from $2.3 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $4.0 million in Q2 2023 to a low of $537000.0 in Q2 2021.
  • Historically, Leases has averaged $2.5 million across 5 years, with a median of $2.6 million in 2025.
  • Biggest five-year swings in Leases: plummeted 84.19% in 2021 and later surged 551.58% in 2022.
  • Year by year, Leases stood at $3.5 million in 2021, then plummeted by 37.73% to $2.2 million in 2022, then decreased by 24.87% to $1.6 million in 2023, then tumbled by 40.87% to $968000.0 in 2024, then soared by 76.34% to $1.7 million in 2025.
  • Business Quant data shows Leases for IMDX at $1.7 million in Q4 2025, $2.3 million in Q3 2025, and $2.5 million in Q2 2025.